Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, 1007, Shimo-Nagakubo, Sunto-Nagaizumi, Shizuoka, 4118777, Japan.
Division of Pathology, Shizuoka Cancer Center, Shizuoka, Japan.
Ann Surg Oncol. 2017 Aug;24(8):2363-2370. doi: 10.1245/s10434-017-5823-5. Epub 2017 Mar 7.
It is difficult to identify patients at high risk of recurrence after pancreatectomy for pancreatic neuroendocrine tumor (PNET) using only the grading classification, especially the G2 category, which includes both benign and low- and high-grade malignant tumors.
Forty-one patients with PNET who underwent pancreatectomy were enrolled in this study. We defined the computed tomography (CT) ratio as the CT value of the tumor divided by that of non-tumorous pancreatic parenchyma using the late arterial phase dynamic CT. The optimal cut-off values for CT ratio and tumor size were determined using p-values that were calculated using the log-rank test.
The optimal cut-off values of CT ratio and tumor size for dividing patients into groups according to the greatest difference in disease-free survival (DFS) were 0.85 (p < 0.001) and 3.0 cm (p < 0.001), respectively. In analysis using Spearman's correlation coefficient, CT ratio (p = 0.007) and tumor size (p = 0.003) were individually associated with the Ki-67 proliferative index. Cox proportional hazard analysis identified that a CT ratio <0.85 (n = 10, p = 0.006) and tumor size ≥3.0 cm (n = 13, p = 0.023) were independent prognostic factors associated with DFS. All patients in the CT ratio ≥0.85 and tumor size <3.0 cm group (n = 23, including seven patients with G2 disease) did not develop recurrence after surgery. On the other hand, 5-year DFS in the CT ratio <0.85 and tumor size ≥3.0 cm group (n = 5, including three patients with G2 disease) was zero.
PNETs with a CT ratio <0.85 and tumor size ≥3.0 cm should be considered as having a high risk of recurrence after pancreatectomy.
仅使用分级分类(尤其是 G2 类)很难确定胰腺神经内分泌肿瘤(PNET)手术后复发风险高的患者,因为其中包括良性和低级别及高级别恶性肿瘤。
本研究纳入了 41 例行胰腺切除术的 PNET 患者。我们定义 CT 比值为使用晚期动脉期动态 CT 测量肿瘤的 CT 值除以非肿瘤胰腺实质的 CT 值。使用对数秩检验计算 p 值确定 CT 比值和肿瘤大小的最佳截断值。
为了根据无疾病生存(DFS)差异最大将患者分组,CT 比值和肿瘤大小的最佳截断值分别为 0.85(p<0.001)和 3.0cm(p<0.001)。使用 Spearman 相关系数分析,CT 比值(p=0.007)和肿瘤大小(p=0.003)分别与 Ki-67 增殖指数相关。Cox 比例风险分析确定 CT 比值<0.85(n=10,p=0.006)和肿瘤大小≥3.0cm(n=13,p=0.023)是与 DFS 相关的独立预后因素。CT 比值≥0.85 且肿瘤大小<3.0cm 组(n=23,包括 7 例 G2 疾病患者)中的所有患者手术后均未复发。另一方面,CT 比值<0.85 且肿瘤大小≥3.0cm 组(n=5,包括 3 例 G2 疾病患者)的 5 年 DFS 为 0。
CT 比值<0.85 且肿瘤大小≥3.0cm 的 PNET 患者应被认为是胰腺切除术后复发风险高的患者。